^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Thyroid Gland Carcinoma
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Melanoma)
    New
    Excerpt:
    Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers

    Excerpt:
    ...- Histologically confirmed cancers (excluding melanoma and papillary thyroid cancer) with a BRAF V600 mutation and that are resistant to standard therapy or for which standard or curative therapy does...
    Trial ID:
    NCT01524978
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)

    Excerpt:
    ...Tumor samples were then sent to a central laboratory to identify activating BRAF V600 mutations. ...
    Trial ID:
    NCT01804140
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379

    Excerpt:
    ...- Confirmation in a CLIA certified laboratory or in an FDA-approved assay that one of the patient's thyroid tumors (primary tumor, recurrent tumor, or metastasis) possesses a BRAF mutation at V600....
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer

    Excerpt:
    ...BRAF V600E mutation detected in the primary tumor or the recurrent/persistent tumor....
    Trial ID:
    NCT01709292
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Exp Clin Cancer Res
    Title:

    Vitamin C sensitizes BRAF V600E thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032

    Published date:
    01/19/2021
    Excerpt:
    PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer...PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAFMT thyroid cancer.
    Secondary therapy:
    leucomethylene Blue
    DOI:
    10.1186/s13046-021-01831-y